Vaccine rally showed value flawed as momentum hedge, quant says

Uncertainty and strategy design meant November 9 rally fell short of covering momentum crash

Vaccine stock effect

It was the news value investors had been waiting for. On November 9, Pfizer announced that its coronavirus vaccine was found to be more than 90% effective in preventing Covid-19 – prompting the sharpest rotation from momentum to value stocks on record.

Some investors hailed it as the start of a long-awaited recovery in value factor strategies, after years of poor performance. But on closer inspection, it looks more like a false dawn.

“It’s really been a disastrous year for value during the

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact [email protected] or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact [email protected] to find out more.

To continue reading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here: